Andrew Aromando - 01 Jan 2026 Form 3 Insider Report for ONCOLYTICS BIOTECH INC (ONCY)

Role
Chief Business Officer
Signature
/s/ Kirk Look, Attorney-in-Fact
Issuer symbol
ONCY
Transactions as of
01 Jan 2026
Net transactions value
$0
Form type
3
Filing time
02 Jan 2026, 16:30:21 UTC
Previous filing
07 Mar 2024
Next filing
13 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Aromando Andrew Chief Business Officer C/O ONCOLYTICS BIOTECH INC., 4350 EXECUTIVE DRIVE, SUITE 325, SAN DIEGO /s/ Kirk Look, Attorney-in-Fact 02 Jan 2026 0001976455

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ONCY Common Shares 25,500 01 Jan 2026 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ONCY Stock Option 01 Jan 2026 Common Shares 750,000 $0.9300 Direct F1, F2
holding ONCY Stock Option 01 Jan 2026 Common Shares 300,000 $1.08 Direct F3
holding ONCY Stock Option 01 Jan 2026 Common Shares 250,000 $0.9900 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests in three equal annual installments beginning on June 25, 2026.
F2 The exercise price is listed in Canadian dollars.
F3 The stock option vests in three equal annual installments beginning on August 15, 2026.
F4 The stock option vests in three equal annual installments beginning on December 15, 2026.

Remarks:

Exhibit 24 - Power of Attorney.